Status:

COMPLETED

A Multiple Dose Study of LY3023703 in Healthy Participants

Lead Sponsor:

Eli Lilly and Company

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

This is a study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream and ...

Eligibility Criteria

Inclusion

  • Overtly healthy individuals based on the history and physical examinations as determined by the investigator
  • Are normotensive (defined as supine systolic blood pressure \[BP\] less than 140 millimeters of mercury \[mm Hg\] and diastolic BP less than 90 mm Hg without the use of any antihypertensives) or results that are judged to be not clinically significant by the investigator

Exclusion

  • Have presence of clinically significant active bleeding or history of bleeding diathesis at the time of screening
  • Have presence of active peptic ulcer disease, gastro-intestinal (GI) bleeding, chronic gastritis, inflammatory bowel disease, or chronic diarrhea
  • Have evidence of other chronic liver disease
  • Have any use of nonsteroidal anti-inflammatory drugs (NSAIDs), celecoxib, aspirin, or acetaminophen (at doses greater than 1 gram per day \[g/day\] within 14 days of admission
  • Have greater than 1 plus pretibial pitting edema or 2 plus ankle or pedal edema

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT01849055

Start Date

May 1 2013

End Date

December 1 2013

Last Update

December 14 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Evansville, Indiana, United States, 47710

A Multiple Dose Study of LY3023703 in Healthy Participants | DecenTrialz